and survivors of COVID–19 with ME/CFS. Such research shall attempt to better understand the underlying cause or causes of ME/CFS to reduce the rate of onset of ME/CFS in COVID–19 survivors or identify effective treatments and improve outcomes for COVID–19 survivors with ME/CFS. (b) Data collection In carrying out subsection (a), the Director of NIH shall implement a system to collect data on ME/CFS, which can be contributed to and utilized by research partners, and which provides for the collection of such data including— (1) epidemiologic information with respect to the incidence, prevalence, and impact of ME/CFS in the United States, COVID–19 patients exhibiting ME/CFS symptoms, and survivors of COVID–19 with ME/CFS